In today’s briefing:
- Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU): An Improved Image
- Additional Points Add to Our Recent Bearish View on Takeda.
- Top Glove Corp (TOPG MK): Volume and ASP Growth Achieved in 3QFY24; Sees Higher Global Demand Ahead
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU): An Improved Image
- Diagnostic imaging provider Capitol Health (CAJ AU) has announced it has entered into a process deed with Integral Diagnostics (IDX AU)
- This non-binding indicative Offer, by way of a Scheme, involves 0.12849 new IDX shares for each share of Capitol. The next step is four weeks of two-way confirmatory due diligence.
- The implied Offer Price under the scrip terms is A$0.3284/share. Should the transaction complete, Integral would hold 63% in the combined group. This is the second Integral/Capitol merger attempt.
Additional Points Add to Our Recent Bearish View on Takeda.
- Production problems of Vyvanse generics seem to be largely resolved with nine of the ten suppliers back in stock.
- Safety concerns with Takeda’s approved psoriasis competitor does raise further concerns as they are both TYK-2 inhibitors.
- The company’s $900 m big restructure and cited areas for margin improvement are not “convincing” and lack detail.
Top Glove Corp (TOPG MK): Volume and ASP Growth Achieved in 3QFY24; Sees Higher Global Demand Ahead
- Top Glove Corp (TOPG MK) achieved 16% QoQ revenue growth in 3QFY24, on 13% sequential volume increase and higher ASP. 3QFY24 operational loss reduced to RM34M from RM59M in 2QFY24.
- Considering the current demand and supply condition, Top Glove expects the ASP to further increase. The company aims to recover its EBITDA margin to pre-pandemic levels of 15% by FY26.
- With rising import alert and expected tariff increase on Chinese manufacturers, the US demand may shift from China to Malaysia. Top Glove is poised to benefit from potential trade diversion.